Avoiding medication conflicts for patients with multimorbidities by Kovalov, Andrii & Bowles, Juliana Kuster Filipe
Avoiding Medication Conflicts for Patients with
Multimorbidities?
Andrii Kovalov1 and Juliana K. F. Bowles2
1 German Aerospace Center (DLR), Simulation and Software Technology
andrii.kovalov@dlr.de
2 School of Computer Science, University of St Andrews
KY16 9SX, St Andrews, UK
jkfb@st-andrews.ac.uk
Abstract. Clinical pathways are care plans which detail essential steps
in the care of patients with a specific clinical problem, usually a chronic
disease. A pathway includes recommendations of medications prescribed
at different stages of the care plan. For patients with three or more
chronic diseases (known as multimorbidities) the multiple pathways have
to be applied together. One common problem for such patients is the ad-
verse interaction between medications given for different diseases. This
paper proposes a solution for avoiding medication conflicts for patients
with multimorbidities through the use of formal methods. We introduce
the notion of a pharmaceutical graph to capture the medications asso-
ciated to different stages of a pathway. We then explore the use of an
optimising SMT solver (Z3) to quickly find the set of medications with
the minimal number and severity of conflicts which is assumed to be
the safest. We evaluate the approach on a well known case of an elderly
patient with five multimorbidities.
1 Introduction
There is an increasing number of people in Europe and in the UK with three
or more long term conditions, also known as multimorbidities. In Europe, the
current number of people with multimorbidities is estimated at around 50 million
[7], and in the UK it is currently around 1.9 million [8]. Chronic diseases often
develop simultaneously in response to common risk factors such as smoking,
diet, ageing, and inactivity [3, 18]. The four most common chronic diseases are
cancer, chronic obstructive pulmonary disease (COPD), coronary heart disease,
and diabetes.
Despite the growing prevalence of chronic disease, strategies for improving
the management of patients with co-morbidities remain under-explored. In clin-
ical settings processes are complex and necessarily rely on a range of interacting
social agents including physicians, administrators and patients who in turn are
influenced by a number of social, technical and organisational factors. This com-
plexity can result in variation in how physicians practice, appropriate care is
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documented, and healthcare costs are managed [19]. To reduce inconsistencies
clinical guidelines have emerged which are based on the best existing evidence
and which aim to support clinical staff and improve the quality of healthcare.
There are currently around 180 clinical guidelines published by the National
Institute for Clinical Excellence (NICE)3. However, current guidelines almost
entirely focus on single conditions. As a result, applying multiple guidelines to
a patient may potentially result in conflicting recommendations for care. In the
UK and Europe there have been calls for improved integration of existing guide-
lines for patients with multimorbidities [12, 7], but this is still very much an open
problem.
To encourage the translation of national guidelines into local protocols, and
subsequently clinical practice, clinical pathways have been developed. Clinical
pathways are care plans which detail essential steps in the care of patients with a
specific clinical problem, usually a chronic disease [6]. These pathways frequently
use graphical descriptions of evidence and options, and are typically represented
in a single or a series of flow charts [9, 16]. A pathway includes recommenda-
tions of medications prescribed at different stages of the care plan. One common
problem for patients with multiple long term conditions is the adverse interac-
tion between medications given for different diseases. We concentrate on such
medication interactions in this paper, and introduce a notion of a pharmaceuti-
cal graph for a chronic disease as a formal representation of the medications and
medication groups underlying a clinical pathway. These pharmaceutical graphs
and the information on known adverse medication conflicts are used to answer
the fundamental question of what is the best care plan and what are the most
effective medications in the treatment of patients with multimorbidities?
The main contribution of our paper is a solution for avoiding medication
conflicts for patients with multimorbidities through the use of formal methods.
We explore the use of an optimising SMT solver (Z3) to quickly find the set of
medications with the minimal number and severity of conflicts which is assumed
to be the safest. We evaluate our approach with a very well known case in the
medical domain taken from [5] of a hypothetical 79-year-old woman with five
long term conditions: hypertension, diabetes mellitus (type 2), osteoarthritis,
osteoporosis and chronic obstructive pulmonary disease (COPD).
This paper is structured as follows. We start by setting the context of our
work and describing some of the most relevant existing related work in Section 2.
Section 3 introduces our notion of pharmaceutical graph which is extracted for
each disease from the corresponding documented clinical pathways. Since our
approach makes use of SMT solvers, in Section 4 we describe how to derive
logical formulae from the pharmaceutical graphs and medication conflicts. Our
approach is evaluated in Section 5, and its performance is compared with other
possible solutions. We conclude our paper in Section 6 with a discussion of
current limitations and ideas for future work.
3 NICE www.nice.org.uk
2 Related Work
The National Institute for Clinical Excellence (NICE) has a considerable num-
ber of documented pathways for care and treatment of diseases including the
most common chronic conditions such as cancer, chronic obstructive pulmonary
disease, coronary heart disease, diabetes, hypertension, osteoarthritis, chronic
heart failure, chronic kidney disease, depression and so on. The pathways are
nonetheless essentially single-disease descriptions, and there is little advice on
how to combine or consider two or more of them when addressing the needs of
patients with multimorbidities. Better approaches for integrated care are lacking
and urgently needed.
In clinical practice, the main suggestion is to enrich pathways with addi-
tional information. This includes recommendations regarding certain comorbidi-
ties, discussion of benefits and risks of treatment, and advice on treating elderly
patients [5, 10, 15].
More recently, the possibility of developing automated techniques for inte-
grated care has drawn attention from the computer science community. Several
approaches were introduced with the aim of formalising and merging existing
single-disease pathways to produce a treatment advice for patients with multi-
ple diseases. A few different approaches are described next.
One approach is to model pathways using ontologies [2, 1, 11]. The authors
focus on eliminating duplicated tasks across different pathways (e.g. blood tests),
reusing the results of common activities and avoiding medication conflicts. Al-
though ontologies are an expressive modelling instrument, the automatic merging
of multiple ontologies seems problematic.
Another approach also making use of ontologies is carried out under the
project GLARE [17] which instead of automatically merging guidelines provides
an interactive interface for clinicians to analyse multiple guidelines at different
levels of detail.
A different approach is shown in [13] where the authors use rewriting rules
to eliminate conflicts in merged guidelines.
A research somewhat similar to ours is presented in [20]. The authors encode
individual pathways as sets of formulas in first-order logic and use an automated
theorem prover to find a combined treatment plan. The medication conflicts are
also represented as logical expressions, and if a conflict is detected then special
‘Revision Operators’ are invoked that rewrite fragments of logical expressions
so that the conflict may disappear. These operators correspond to some medical
actions that are performed to resolve a conflict (such as the co-prescription of
an additional medication). If the Revision Operators cannot resolve the conflict
then the algorithm fails to produce any treatment suggestion.
Our approach is similar in that we also transform medical knowledge into
logical expressions and use a tool (an SMT solver rather than a theorem prover)
to automatically produce treatment advice. However, unlike [20], we take into
account the medical utility of the produced advice, and try to generate not just
any possible advice, but the best and safest possible recommendation with re-
spect to given knowledge on medication conflicts. The advantage of our approach
is that we will be able to provide a solution even if certain conflicts cannot be
avoided. In the case of patients with 5 or more multimorbidities, it is likely that
some conflicts are indeed unavoidable and the aim in such cases is to reduce it
to a more favourable alternative.
3 Pharmaceutical Graphs
The goal of our research is to help clinicians make more informed decisions, and
more concretely medication prescriptions that result in the minimal amount and
severity of medication conflicts. In other words, we would like to find the safest
set of medications for a patient with multiple diseases. We take into account
three types of conflicts:
– Drug-drug conflicts (when two medicines taken together have some negative
effect or decrease effectiveness of each other),
– Drug-disease conflicts (e.g. any medication that increases blood pressure
conflicts with hypertension),
– Drug-patient conflicts (personal medication intolerances and allergies).
To detect and avoid these conflicts we need to know which medications can
be prescribed according to the clinical pathway. As the pathways are written
informally in natural language, we first need to create a formal representation
of a pathway. We developed a representation which we call a pharmaceutical
graph which is a directed acyclic graph with one initial node where the nodes
represent medication prescriptions. Normally a clinical pathway suggests several
alternative medications for the doctor to choose from. Likewise, in our pharma-
ceutical graph a node can contain multiple medications one of which should be
prescribed.
Examples of pharmaceutical graphs for Diabetes Melitus and Hypertension
are shown in Fig. 1. For clarity we included a dummy initial node with the
disease name that does not contain any medications. For Diabetes this dummy
node is also necessary for branching.
Often the pathways recommend not a single medication, but a medication
group such as Sulfonylurea. In this case we include all individual Sulfonylureas
into the node. In Fig. 1 for the medication groups the number of individual
medications is shown in brackets. It is important to list all the medications in a
group because they might have different conflicts.
Pharmaceutical graphs capture two features of the original pathways: the
structure (ordering and branching) and the advised medications. A maximal
path in a pharmaceutical graph (from the initial node to a leaf node) represents
a choice of medications in a treatment plan. For example, one maximal path
(prescription) in the Diabetes graph could be Metformin, Sitagliptin, Insulin.
Having such maximal paths for multiple pharmaceutical graphs, we can de-
tect the above mentioned three types of drug-related conflicts in them.
Additionally, we consider the severity of medication conflicts and how suit-
able given medications are known to be for the treatment of certain conditions.
Fig. 1. Pharmaceutical graphs for Diabetes and Hypertension based on NICE path-
ways. ACE - angiotensin-converting-enzyme, ARB - angiotensin receptor blocker, CCB
- calcium channel blocker. The numbers in brackets represent the number of individual
medications in a group.
To distinguish between major and minor conflicts we assign negative integer
scores to them. Similarly, we assign positive scores to the medications depend-
ing on their efficacy. Our aim is to obtain a treatment plan with the highest
score considered to be the safest and most effective for a particular patient. In
this way we can produce a reasonable treatment advice even when certain con-
flicts cannot be avoided. Note that it is outside the scope of our work to assign
scores to drugs. The safety and effectiveness of drugs is subject to evaluations
carried out in clinical pharmacology and biopharmaceutics data research. Phar-
maceutical companies assign scores to drugs based on evidence-based safety and
effectiveness.
Our question is, therefore, formulated as follows: Having a set of pharmaceu-
tical graphs and a set of conflicts, what are the prescriptions (maximal paths)
for all the graphs that result in the highest total score? The total score here is
the sum of the positive scores of all the chosen medications and the negative
scores of the triggered conflicts. Thus, we have transformed a medical problem
into a computation problem. In the next section we show how we tackle it using
an optimising SMT (satisfiability modulo theories) solver.
4 Transformation into an SMT problem
SMT solvers extend the boolean satisfiability problem (SAT) with additional
theories for integers, arrays, etc. Given a predicate over boolean and integer
variables, an SMT solver can check if there exists an assignment for the variables
that turns the predicate into true. If such assignments exist, an SMT solver
produces one of these assignments.
We are using an SMT solver Z3 developed at Microsoft research [14] which
has a built-in optimisation functionality. In other words, Z3 can produce not
just any satisfying assignment but an optimal assignment with respect to some
objective function [4].
The core idea of our work is to translate the pharmaceutical graphs and
the medication conflicts into logical and arithmetic expressions and use Z3 to
generate maximal paths for the pharmaceutical graphs with the highest possible
total score.
There are two parts of this translation that we would like to discuss in the
following subsections - the representation of the graph structure and the repre-
sentation of the medications and conflicts along with their scores.
4.1 Translating the graph structure
We need to translate the structure of the pharmaceutical graphs into logical
expressions and make Z3 produce a maximal path.
First, we shrink the original pharmaceutical graph in order to reduce the
number of variables we need to represent its structure (see Fig. 2).
Fig. 2. Original pharmaceutical graph with branches shown in grey (left) and the
shrinked branch graph (right).
To do this, we divide the nodes of the pharmaceutical graph into different
branches. A branch here is the longest possible sequence of nodes where there
is a path between the first and the last node, and along this path all the nodes
except the last one have exactly one outgoing edge, and all the nodes except the
first one have exactly one incoming edge. The branches are graphically shown in
Fig. 2 with grey regions.
An important property of such a branch is that for any maximal path in the
pharmaceutical graph either the whole branch is on the path or the whole branch
is not on the path. Therefore, we can treat a maximal path as a sequence of
branches. If we substitute each branch with a single node, we will get a shrinked
branch graph (see Fig. 2, right) that will have the same maximal paths as the
original pharmaceutical graph (in terms of branch sequences).
Our idea is to create a boolean variable for each branch and use Z3 to assign
these branch variables to true or false so that there will be one maximal path
consisting of ‘true’ branches and all the rest will be ‘false’. To do this, we specify
logical assertions that would filter out all the invalid assignments of the branch
variables (that do not make one maximal path). We tried and compared two
different approaches to produce these logical assertions.
The first and a more naive approach, which is taken in [20], is to explicitly
enumerate all the maximal paths. Illustrating this for the graph in Fig. 2, we
obtain the following logical statement:
(Br0 ∧ Br1 ∧ Br3 ∧ Br5 ∧ ¬Br2 ∧ ¬Br4 ∧ ¬Br6 )∨
(Br0 ∧ Br1 ∧ Br4 ∧ Br5 ∧ ¬Br2 ∧ ¬Br3 ∧ ¬Br6 )∨ . . .
For the second approach, we designed a set of branching rules that are applied
to every node in the graph and produce some logical statements. The rules are
as follows:
1. The initial branch is always true
2. If the current branch is true then one of its direct successors is true and the
other direct successors are false (if there are direct successors)
3. If all the direct predecessors of the current branch are false then the current
branch is false (if there are direct predecessors)
For example, for branches Br0, Br1 and Br4 in Fig. 2 the following state-
ments will be generated.
Br0 (rule 1 for Br0)
Br0 =⇒ (Br1 ∧ ¬Br2 ) ∨ (¬Br1 ∧ Br2 ) (rule 2 for Br0)
Br1 =⇒ (Br3 ∧ ¬Br4 ) ∨ (¬Br3 ∧ Br4 ) (rule 2 for Br1)
¬Br0 =⇒ ¬Br1 (rule 3 for Br1)
Br4 =⇒ (Br5 ∧ ¬Br6 ) ∨ (¬Br5 ∧ Br6 ) (rule 2 for Br4)
¬Br1 ∧ ¬Br2 =⇒ ¬Br4 (rule 3 for Br4)
We are interested in the variable assignments that turn these statements true
for all the nodes of a branch graph, so we pass these statements as assertions to
Z3, and get an assignment representing a maximal path.
Proposition 1. The three branching rules ensure that exactly one maximal path
in a branch graph will consist of true nodes, and all the other nodes will be false.
Proof. First we will show that there will be a maximal path consisting of true
nodes. The initial node in the branch graph will be true (rule 1). This means
one of its direct successors will also be true (rule 2), one of the direct successors
of this true successor will be true as well (rule 2) and so on until a leaf node for
which rule 2 will not produce any statements. Therefore, there will be a path
starting in the initial node and finishing in a leaf node (i.e. a maximal path)
consisting of true branches.
We will now prove by contradiction that no other node can be true. Let us
assume there is a node A which is true and does not belong to this maximal path.
A is not the initial node (because otherwise it would belong to a maximal path
by definition). Therefore, A has some direct predecessor B. This predecessor
may or may not belong to the maximal path. If it belongs to the maximal path
it should have another direct successor C apart from A which is true and lies
on the path. Consequently, A cannot be true because according to rule 2 all the
other direct successors of B apart from C should be false.
If no direct predecessor of A belongs to the maximal path, at least one of
them should be true (otherwise A would be false according to rule 3). This true
predecessor should also have a true predecessor (rule 3) and so on, so there will
be a chain of true predecessors. Our graph is acyclic and has only one initial
node, so if we follow the edges backwards from any node we will always come
to the initial node which lies on the maximal path. Therefore, in this chain of
true predecessors there will be some node D which has a direct predecessor that
belongs to the chosen maximal path. As we already showed above, this node D
cannot be true. We have come to a contradiction, so a true node A that does
not belong to the maximal path cannot exist.
uunionsq
It is hard to tell whether the naive approach or the approach with the branch-
ing rules is more suitable for our task because it depends on how Z3 processes
the statements internally. We compare both approaches in Section 5.
4.2 Translating medications, conflicts and scores
Aside from having a maximal path in the pharmaceutical graph we also need to
choose the individual medications in every node along this path. Therefore, if a
node belongs to a ‘true’ branch we want to pick one medication. Additionally,
as we already mentioned, every medication has an integer score which we also
need to pass to Z3.
For example, in the Diabetes graph shown in Fig. 1 there is a node ‘Metformin
or Sulfonylurea’. Let us assume this node has the identifier N1 and belongs to
a branch Br1, the score of Metformin is 100 and the score of Sulfonylurea is 70.
Sulfonylureas are a medication group rather than a single medication, but we
ignore this for the moment.
The assertions we generate for this node are shown below.
Br1 =⇒ (Metformin ∧ ¬Sulfonylurea) ∨ (¬Metformin ∧ Sulfonylurea)
¬Br1 =⇒ ¬Metformin ∧ ¬Sulfonylurea
N1 Score = if (Metformin) then 100 else if (Sulfonylurea) then 70 else 0
For every medication we create a boolean variable that denotes whether it
is prescribed or not. If the node lies on the chosen maximal path (Br1 is true)
then one medication out of two will be set to true, otherwise both will be false.
We also introduce an integer variable N1 Score which will get different value
depending on which medication is picked (Z3 supports integers and if-then-else
expressions). We create score variables for every node of the pharmaceutical
graph and then sum them to get the total medication score.
As for the conflicts, we represent them as integer variables in the following
way.
Conflict1 Score = if (Nadolol ∧Diabetes) then -5000 else 0
Conflict2 Score = if (Sitagliptin) then -1000 else 0
Conflict3 Score = if (Metformin ∧Acarbose) then -100 else 0
Here Conflict1 is a major drug-disease conflict, Conflict2 is a moderate al-
lergy and Conflict3 is a minor drug-drug conflict.
The total score is then the sum of the medication scores (which are non-
negative) and the conflict scores which are negative when a conflict is triggered.
To put it all together, we start with a set of pharmaceutical graphs corre-
sponding to the diseases of a particular patient and a set of conflicts which may
arise. Then we generate Z3 code as explained above and run Z3 with the total
score as the objective function. The output of Z3 are the assignments of the
branch and medication variables that correspond to a treatment plan with the
highest score.
In the next section, we show an example of using this system and discuss the
results.
5 Evaluation
To evaluate our approach, we model a medically well known case from [5] of a
hypothetical 79-year-old woman with five diseases: hypertension, diabetes mel-
litus (type 2), osteoarthritis, osteoporosis, and chronic obstructive pulmonary
disease (COPD).
5.1 Medical data collection
We used two sources of medical information. We use the clinical pathways for
the diseases as documented by NICE and an online portal Drugs.com4 to get
the data on the medication groups and conflicts.
4 http://www.drugs.com
NICE pathways are available in the form of flowcharts with supporting text.
A fragment of the diabetes pathway is shown in Fig. 3. On the left side it shows
the graphical representation of the current aspect of the pathway (in the example
the therapy for lowering blood-glucose for patients with type 2 diabetes). Details
for the current node being highlighted (Metformin) are shown in the text on the
right side.
Fig. 3. Fragment of a NICE clinical pathway for type 2 diabetes.
Given such a documented pathway for a long term condition, the first step
is to extract the information about the medications and transform it into our
pharmaceutical graph. We did this manually for all five long term conditions
considered. The resulting pharmaceutical graphs are shown in Fig. 1 and Fig. 4.
When pathways recommended a medication group, we expanded it based
on the data from Drugs.com. In total for all five diseases, our pharmaceutical
graphs contain 127 medications.
To get all the possible drug-drug conflicts, we used an interaction checker of
Drugs.com5. To get the drug-disease conflicts, we examined the medication pro-
files on Drugs.com. We only considered drug-drug conflicts where both conflict-
ing medications appear in our pharmaceutical graphs and drug-disease conflicts
5 http://www.drugs.com/drug interactions.html
Fig. 4. Pharmaceutical graphs for Osteoartritis, Osteoporosis and Chronic Obstructive
Pulmonary Disease (COPD) based on NICE pathways. NSAID - nonsteroidal anti-
inflammatory drug, COX-2 - Cyclooxygenase-2.
where the medication appears in the pharmaceutical graphs and the disease is
one of the considered five diseases. The summary of the conflicts is shown in
Table 5.1. As we can see, the number of conflicts is far too large to analyse
manually. We did not include any drug-patient conflict in our experiment.
Table 1. Conflicts summary
Major Moderate Minor Total
Drug-drug 270 3038 178 3486
Drug-disease 47 33 0 80
Total 317 3071 178 3566
As for the score values, we assigned medication scores according to the rating
on Drugs.com in the range from 0 to 100. For minor, moderate, and major
conflicts we assigned values -100, -1000, -5000 respectively.
Ideally we would like medical experts to assign score values, however, for
our experiment we just assigned values that seemed reasonable to us and in
accordance to the pharmaceutical ratings mentioned above.
5.2 Experiment results
To run this experiment, we created a simple application which takes the phar-
maceutical graphs and the conflicts as an input, generates the corresponding Z3
code, runs it, parses Z3 output and renders the resulting optimal set of maximal
paths using Graphviz.
The output of our application for this experiment (with 5 diseases, 127 med-
ications, and 3566 conflicts) is shown in Fig. 5. As we can see, the best recom-
mendation still causes four moderate conflicts, and the total score is dominated
by the score of these conflicts. In this case the doctor might decide to exclude
some medications from the treatment, because the negative effect caused by the
conflicts may outweigh the benefits.
Fig. 5. Optimal medication prescriptions for a hypotetical patient with five diseases
generated by Z3.
To evaluate the performance of the system, we ran the experiment on an off
the shelf laptop with 16 GB RAM and a quad-core 2.6 GHz processor. We tried
both approaches to produce logical assertions discussed in Subsection 4.1. The
average run time with the explicit enumeration of maximal paths is 7.6 seconds,
while with the branching rules it is 8.1 seconds, so the explicit enumeration
works marginally faster for this case.
In our opinion, the system runs fast enough to be used in a clinical environ-
ment as a decision support tool.
The real run time is likely to be less because doctors might exclude medica-
tions that are not certified or that are known to have many negative interactions.
Additionally, doctors might pick a particular medication or branch manually and
therefore reduce the amount of computations required. Moreover, it is only a mi-
nority of patients that will have five or more concomitant conditions.
5.3 Other approaches
In addition to using optimising Z3, we evaluated several other approaches that
turned out to be less efficient.
Before the optimising version of Z3 was released, we tried iterative SMT
solving using a hill-climbing and a dichotomy approaches. In a hill-climbing
approach we first obtained some initial solution with score S0, and then added
an assertion FinalScore > S0. The solver would return another solution with
score S1, S1 > S0. We then continued to get better and better solutions until we
hit ‘unsatisfiable’.
In the dichotomy approach we used the fact that the best score lies in a
bounded interval. It cannot be greater than the sum of all the medication scores
and cannot be less then the sum of all the negative conflict scores. We calculated
this interval and iteratively halved it by examining the mid-point. We used an
SMT solver to check if a solution existed with the score greater or equal to this
mid-point, and depending on the result took the upper or the lower half of the
interval until we reached an interval containing only the highest score.
These approaches are much slower than using the built-in optimising Z3
functionality (run time is over an hour for the experiment with five diseases
compared to under 10 seconds for the optimising Z3).
We also tried to find the optimal solution using A*. This worked compara-
tively well on smaller problems, but for the experiment with five diseases our
A* implementation ran out of memory (1 Gb) after a minute of calculation.
This was due to the growth of the set of visited states. We defined a state as a
set of incomplete or complete paths for the input pharmaceutical graphs. Every
possible combination of medications resulted in a new state, leading to a very
large search space.
We conclude from this evaluation that the approach based on SMT solving
is more appropriate than A* for heavily constrained problems (in our case the
constraints are the numerous medication conflicts). For such problems it is hard
to define a good cost under-approximation function for A* which makes the
algorithm explore wrong directions.
6 Conclusions
Our work shows that a treatment advice for a patient with multimorbidities can
be produced automatically using an SMT solver. This approach can be used in
a clinical decision support tool as it works reasonably fast. Our work acts as a
proof of concept for a tool which is being developed for clinicians.
Additionally, the approach allows us to choose a certain medication or a
pathway branch manually. We believe that this kind of interactive analysis can
be useful to get some insight into the different treatment options and their
consequences.
Our current way of modelling the clinical pathways and underlying medica-
tion conflicts also has some limitations.
First of all, the dosages and the timing information for conflicts should be
taken into account. Some interactions may arise only when the medications are
taken simultaneously or if the dose is large enough.
Secondly, it is not clear how to assign numerical scores to medications in
general, and especially in the case of branching. The branches may contain dif-
ferent number of medications, and a longer branch will likely get a higher score.
Therefore, the scores should be somehow balanced.
Finally, our current approach aims at avoiding, but not resolving conflicts.
For instance, sometimes it is necessary to co-prescribe additional medications in
order to mitigate a certain adverse interaction, and we currently do not consider
this issue.
In future work we aim to address these limitations, and eventually create
a tool that will help clinicians deliver better care for an increasing number of
patients suffering from multimorbidities.
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